OrbiMed’s Sinovac Biotech, Ltd SVA Stock Holding History

OrbiMed’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$184M	Hold	2,718,735	–	–	3.66%	5
2025 Q4	$184M	Hold	2,718,735	–	–	3.77%	4
2025 Q3	$184M	Hold	2,718,735	–	–	4.33%	4
2025 Q2	$334M	Hold	2,718,735	–	–	8.34%	1
2025 Q1	$334M	Hold	2,718,735	–	–	7.96%	1
2024 Q4	$334M	Hold	2,718,735	–	–	6.87%	2
2024 Q3	$340M	Hold	2,718,735	–	–	6.18%	2
2024 Q2	$340M	Hold	2,718,735	–	–	6.71%	1
2024 Q1	$340M	Hold	2,718,735	–	–	6.23%	1
2023 Q4	$340M	Hold	2,718,735	–	–	6.79%	1
2023 Q3	$340M	Hold	2,718,735	–	–	7.22%	1
2023 Q2	$340M	Hold	2,718,735	–	–	6.16%	1
2023 Q1	$340M	Hold	2,718,735	–	–	6.67%	1
2022 Q4	$340M	Hold	2,718,735	–	–	6.5%	1
2022 Q3	$341K	Hold	2,718,735	–	–	6.32%	1
2022 Q2	$350K	Buy	+2,718,735	New	+$349K	6.33%	1
2022 Q1	–	Sell	-2,839,500	Closed	-$72.7M	–	171
2021 Q4	$72.7M	Hold	2,839,500	–	–	0.93%	36
2021 Q3	$78.4M	Hold	2,839,500	–	–	0.86%	35
2021 Q2	$76.8M	Hold	2,839,500	–	–	0.78%	43
2021 Q1	$72M	Hold	2,839,500	–	–	0.67%	46
2020 Q4	$72M	Hold	2,839,500	–	–	0.63%	43
2020 Q3	$27.3M	Hold	2,839,500	–	–	0.34%	75
2020 Q2	$25.5M	Hold	2,839,500	–	–	0.36%	68
2020 Q1	$17.2M	Hold	2,839,500	–	–	0.29%	72
2019 Q4	$17.2M	Hold	2,839,500	–	–	0.24%	71
2019 Q3	$16.6M	Hold	2,839,500	–	–	0.32%	70
2019 Q2	$16.6M	Hold	2,839,500	–	–	0.26%	78
2019 Q1	$18.4M	Hold	2,839,500	–	–	0.28%	78
2018 Q4	$19.7M	Hold	2,839,500	–	–	0.36%	70
2018 Q3	$21.6M	Hold	2,839,500	–	–	0.26%	83
2018 Q2	$21.2M	Hold	2,839,500	–	–	0.25%	88
2018 Q1	$24.4M	Hold	2,839,500	–	–	0.3%	74
2017 Q4	$22.4M	Buy	2,839,500 +172,000	+6%	+$1.29M	0.28%	77
2017 Q3	$18.8M	Hold	2,667,500	–	–	0.18%	86
2017 Q2	$18M	Hold	2,667,500	–	–	0.19%	83
2017 Q1	$15.3M	Hold	2,667,500	–	–	0.17%	84
2016 Q4	$15.7M	Hold	2,667,500	–	–	0.2%	74
2016 Q3	$15.7M	Hold	2,667,500	–	–	0.18%	84
2016 Q2	$15.8M	Hold	2,667,500	–	–	0.17%	80
2016 Q1	$17M	Hold	2,667,500	–	–	0.18%	68
2015 Q4	$15.3M	Hold	2,667,500	–	–	0.14%	78
2015 Q3	$13.6M	Hold	2,667,500	–	–	0.14%	83
2015 Q2	$14M	Hold	2,667,500	–	–	0.12%	95
2015 Q1	$13.2M	Sell	2,667,500 -154,000	-5%	-$759K	0.11%	93
2014 Q4	$14.8M	Hold	2,821,500	–	–	0.14%	87
2014 Q3	$13.6M	Buy	2,821,500 +1,184,000	+72%	+$6.36M	0.14%	88
2014 Q2	$9.24M	Hold	1,637,500	–	–	0.11%	90
2014 Q1	$11.8M	Hold	1,637,500	–	–	0.15%	82
2013 Q4	$10M	Sell	1,637,500 -246,700	-13%	-$1.49M	0.15%	81
2013 Q3	$11.3M	Hold	1,884,200	–	–	0.2%	72
2013 Q2	$7.41M	Buy	+1,884,200	New	+$7.01M	0.16%	89

Other funds holding SVA

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

OrbiMed's SVA Position: Q1 2026 in Review

OrbiMed held its Sinovac Biotech, Ltd (SVA) position steady in Q1 2026 at 2,718,735 shares worth $184M. The position accounts for 3.66% of the portfolio, ranked #5.

OrbiMed first reported a position in SVA in Q2 2013 and has held it in 51 quarters since. The position peaked at $340M in Q3 2024. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

OrbiMed held 2,718,735 shares of Sinovac Biotech, Ltd worth $184M as of Q1 2026.
OrbiMed left its Sinovac Biotech, Ltd share count unchanged in Q1 2026.
Sinovac Biotech, Ltd made up 3.66% of OrbiMed's portfolio in Q1 2026, its #5 holding.
OrbiMed first reported a position in Sinovac Biotech, Ltd in Q2 2013 and has held it in 51 quarters since.
OrbiMed's Sinovac Biotech, Ltd position peaked at $340M in Q3 2024.
28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.